Ramsey Lake and Dalton push cancer drug candidate closer to market.

The article reports on the alliance between drugmaker Ramsey Lake Pharma and pharmaceutical chemistry firm Dalton Pharma Services as of April 2016 that led to the development of cancer drug VR23. Topics include the firms' push for the cancer drug candidate closer to market, the need to carry out a systematic toxicology study that would pass regulatory muster, and the plan to start clinical trials by 2018.